Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Decreased Frontal Lobe Gray Matter Perfusion in Cognitively Impaired Patients with Secondary-Progressive Multiple Sclerosis Detected by the Bookend Technique.
Treatment of facial myokymia in multiple sclerosis with botulinum toxin.
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple SclerosisImpact of Fingolimod Therapy in Multiple Sclerosis.
Deep 3D Convolutional Encoder Networks with Shortcuts for Multiscale Feature Integration Applied to Multiple Sclerosis Lesion Segmentation.
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
Transcriptional enhancers: from properties to genome-wide predictions.
Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab.
Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
mfERG_LAB: Software for processing multifocal electroretinography signals.
Sex ratio of multiple sclerosis in Canada: a longitudinal study.
Rehabilitation in transverse myelitis.
Guillain-Barré syndrome in Colombia: where do we stand now?
Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells.
Agreement between physician's recommendation and fitness-to-drive decision in multiple sclerosis.
MiR-126: a novel route for natalizumab action?
Iron Level and Myelin Content in the Ventral Striatum Predict Memory Performance in the Aging Brain.
Pathogenesis of multiple sclerosis via environmental and genetic dysregulation of N-glycosylation.
Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study.
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo.
A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.
European medicines agency's committee for medicinal products for human use issues positive opinion on marketing authorisation application for Fampyra
Laquinimod Halted MS Disability But Not Relapses
Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab.

Pages